Drug intelligence / Profile preview

dexanabinol + carboplatin

Development stage: Unknown
Lead developer: e-Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

Dexanabinol + carboplatin is an investigational combination therapy being studied for the treatment of advanced solid tumors and brain cancer. Dexanabinol (HU-211, ETS2101) is a synthetic cannabinoid derivative that acts as an NMDA antagonist with neuroprotective properties, while carboplatin is a platinum-containing chemotherapy agent that destroys rapidly dividing cancer cells by interfering with DNA replication. This combination is being evaluated in early clinical trials for its potential synergistic effects against advanced cancers.

Targets

DRD1 (Dopamine D1 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)DNA

Beyond the preview

Go deeper on dexanabinol + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexanabinol + carboplatin.

Explore the full profile